Australia markets closed

Novo Nordisk A/S (NVO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
128.40+0.35 (+0.27%)
At close: 04:00PM EDT
128.60 +0.20 (+0.16%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close128.05
Open128.39
Bid128.40 x 1200
Ask128.60 x 1100
Day's range127.79 - 130.16
52-week range75.56 - 138.28
Volume3,500,469
Avg. volume5,233,985
Market cap572.925B
Beta (5Y monthly)0.17
PE ratio (TTM)47.38
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.37 (1.07%)
Ex-dividend date22 Mar 2024
1y target estN/A
  • Reuters

    Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

    Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors. Novo Nordisk's popular obesity drug Wegovy and Eli Lilly's in demand Zepbound are GLP-1 drugs. Siemssen said he expects sales related to GLP-1 medicines to surpass 100 million euros this year and to reach at least 350 million euros ($379 million) within the next three years, based on actual contracts and orders.

  • Zacks

    2 Top Biotech Buyout Candidates

    The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities

  • Zacks

    Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

    While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.